Merck & Co. stock gains as analysts upgrade rating and investors weigh pipeline risk

Merck & Co. stock (ISIN US58933Y1055) traded at USD 146.63 on the New York Stock Exchange on September 20, 2026, leaving the pharmaceutical group valued at roughly USD 362.11 billion and positioning the shares well above their 52-week low but still below the recent high.

Stock trades near upper half of 52-week range

According to an overview from a US retail brokerage on September 20, 2026, Merck & Co. stock moved during the session between an intraday low of USD 145.74 and a high of USD 147.84, before stabilizing around USD 146.63 in regular trading on the New York Stock Exchange.

The same snapshot shows a 52-week trading range from USD 77.58 at the low end to USD 156.92 at the high end, so at USD 146.63 the current price stands about USD 69.05 above the 52-week low and roughly USD 10.29 below the 52-week high, placing Merck & Co. stock in the upper segment of its one-year band as of September 20, 2026.

Valuation reflects expected earnings rebound

A recent fundamental analysis published on September 20, 2026 notes that Merck & Co. trades at about 117.5 times trailing earnings, a level described as roughly 42 percent above its five-year median price-to-earnings multiple as investors anticipate a sharp recovery in profitability.GetStockReport The same analysis points out that consensus expectations imply a move toward approximately 15 times forward earnings, underscoring how much of the current valuation rests on the assumption that recent profit pressure will be temporary rather than structural.GetStockReport

For investors, the spread between the current trailing multiple of 117.5 times and the envisaged forward level near 15 times reflects a quantified comparison that frames both the potential upside if earnings rebound and the downside risk if margins remain compressed. At the same time, the high trailing valuation multiple relative to its own history suggests that Merck & Co. stock is priced for a significant improvement in profitability over the coming quarters.

Recent acquisition costs weigh on margins

An in-depth feature from a Japanese business publication dated September 20, 2026 highlights that Merck & Co.’s share price has advanced by roughly 87 percent over the past year, rising from about USD 79 to around USD 147, even though reported earnings have not kept pace with the stock performance.Forbes Japan The article notes that Merck’s revenue over the most recent twelve-month period amounted to USD 66.6 billion, representing year-on-year growth of about 4.6 percent, while operating margin over the same period stood at 10.5 percent compared with an average of 22.4 percent over the prior three years.Forbes Japan

According to this analysis, the bulk of the margin compression traces back to a single major acquisition, for which Merck recognized approximately USD 5.7 billion in costs in the second quarter of 2026, equivalent to about 9 percent of its annual revenue.Forbes Japan The target, described as a biopharmaceutical company acquired to secure a promising chronic myeloid leukemia drug candidate designated MK-4208, is intended to strengthen Merck’s oncology pipeline, with the cost absorbed in current financials while any revenue benefit is expected only in future years.

Keytruda concentration remains a central risk

The same feature underscores that pipeline expansion has become critical because Merck & Co. faces a pronounced revenue concentration risk: in the second quarter of 2026, the company’s flagship cancer immunotherapy franchise Keytruda accounted for slightly more than half of total sales.Forbes Japan For shareholders, that figure quantifies how dependent Merck & Co. currently is on a single drug family, making regulatory, competitive and patent developments around Keytruda a key risk factor for the stock.

This concentration also helps explain why, despite only a mid-single-digit revenue increase of 4.6 percent over the last twelve months, Merck & Co. stock has outperformed its own earnings trajectory: investors appear to be assigning value not only to current cash flows but also to the potential of new oncology candidates to diversify the revenue base as Keytruda approaches future loss-of-exclusivity milestones.Forbes Japan

Analyst sentiment and rating changes

A broker research alert from September 20, 2026 reports that a stock-picking service upgraded its view on Merck & Co., Inc. shares, citing improved relative valuation and confidence in future earnings normalization.MarketBeat The same overview notes that Merck & Co. stock opened at USD 146.53 on the last completed trading day and confirms the one-year price range between USD 77.58 and USD 156.92, figures that match the retail brokerage snapshot as of September 20, 2026.

While the exact rating terminology and price target adjustments are not detailed across the available summaries, the combination of a rating upgrade and the high trailing valuation multiple suggests that analysts see the recent profit pressure as a phase rather than a new normal. Consensus expectations for a move toward about 15 times forward earnings, compared with 117.5 times trailing, show that much of the debate around Merck & Co. stock now centers on how quickly margins can recover as acquisition costs roll off and new products contribute to revenue.GetStockReport

Stock level and investor takeaway

Based on price data as of September 20, 2026, Merck & Co. stock at USD 146.63 on the New York Stock Exchange trades roughly 89.0 percent above its 52-week low of USD 77.58 and about 6.6 percent below its 52-week high of USD 156.92, a positioning that reflects both strong past performance and lingering caution as investors balance pipeline-driven optimism with margin and concentration risks.

More news and analyses on Merck & Co. stock